CTOs on the Move

Consultants for Clinical Res

www.ccrstudy.com

 
Consultants for Clinical Res is a Cincinnati, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.ccrstudy.com
  • 2925 Vernon Pl Ste 200
    Cincinnati, OH USA 45219
  • Phone: 513.872.4549

Executives

Name Title Contact Details

Similar Companies

Global Trading Partners Inc

Global Trading Partners Inc is a Carlsbad, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

More Diagnostics Inc

More Diagnostics Inc is a Los Osos, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

NeoGenomics

NeoGenomics Laboratories is a leading cancer diagnostic reference laboratory that has provided high-quality cancer testing and partnership programs to pathologists and oncologists for over 10 years. We work every day to achieve our common purpose of saving lives by improving patient CARE through Communication, Accuracy, Reliability, and Efficiency. Our areas of expertise include cancer cytogenetics with industry-leading turnaround times; hematologic and solid tumor FISH testing with the largest menu of technical-only services available; 10-color flow cytometry; IHC supported by an extensive antibody library; and over 100 molecular oncology tests comprising the most comprehensive combination of multiparameter profiles and targeted biomarker tests in the industry. Our technical-only testing programs feature on-demand or live training and are available to pathologists who wish to sign out FISH, flow cytometry, and/or IHC. NeoGenomics` extremely fast test development cycle means we are highly responsive to therapy development and guideline changes, and test design always involves a balance of convention and innovation.

Hardman Pathology

Hardman Pathology is a Athens, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kaleido Biosciences

Kaleido Biosciences is a clinical-stage biotechnology company engaged in the development of novel chemistries that unlock the power of the microbiome to revolutionize health. The Company has built the first R&D engine to systematically create, discover, and develop interventions that activate metabolic processes in the microbiome to treat disease and maintain health. Since its founding in 2015 by Flagship VentureLabs, Kaleido has advanced candidate products into clinical studies across programs in rare genetic diseases, oncology and infectious disease, and has generated more than 3,000 days of human clinical data. The Company is also creating consumer products that optimize the microbiome`s natural roles in promoting health.